Two promising young start-ups win scholarships
Janssen Campus the Netherlands has made available scholarships for 2 promising candidates from young start-up companies.
This year, the scholarships have been awarded to Gerard Boink, PhD (CEO at PacingCure BV, the Netherlands) and Sarah Triest, PhD (scientist at Confo Therapeutics, Belgium). Gerard and Sarah will participate in the 3-part blended course Clinical Development, a highly rated course from Paul Janssen Futurelab. The scholarship is for start-ups who plan to run their first-in-human clinical trial within the next 1.5 years.
During the course, they will use Question-Based Clinical Development to design the optimal clinical developmental program for their product. The course includes an online introduction course, an interactive on-campus course with cases based on real R&D projects from industry and an extended course focused on writing a clinical trial proposal with guidance from an experienced mentor.
The online course is now running and a new round is planned to take place in spring next year. The on-campus courses will take place in June 2020.
Winners of the start-up scholarships 2019.
Articles from our blog
This may be interesting for you
How to become a maker of tomorrow’s medicines using Real Options Theory
Paul Janssen Futurelab Leiden offers a new international blended education & training program for talented biomedical scientists on the development of novel medical interventions using the Real Options Theory. The aim is that these future chief scientific officers will change the entire drug development process.
And the winner is .... Laurel Schunselaar
Laurel Schunselaar (LUMC) is the winner of the Paul Janssen Futurelab Nomination Letter 2019 for the best clinical proposal entitled ‘A phase Ib dose finding study with aclarubicin in patients with metastasized uveal melanoma.’ The letter will be submitted with the research proposal to ZonMw’s Rational Pharmacotherapy Program (GGG) for a half a million grant.
What drives our alumni?
What drives our course participants and alumni? These entrepreneurial biomedical professionals from academia and industry all work to improve human health. What is their motivation to do what they do? What is their vision for the future of their field?